Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

High-risk: early-phase trial registry

1 of 2 indexed High-risk trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

High-risk: 2 US clinical trials tracked, 1 recruiting.

High-risk is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is KDH Research & Communication, running 1 of these trials.

Enrollment posture brief

Registry condition high-risk

OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%High-risk (this)50%
Open-enrollment share among volume-matched conditions near High-risk

High-risk lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for High-risk on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. High-risk is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on High-risk records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Treatment 3: Part 2 of GRIN (Lesson 1, 5-8) Other
1 trials
Treatment 2: Part 1 of GRIN (Lessons 1-4) Other
1 trials
Treatment 1: Full GRIN course (Lessons 1-8) Other
1 trials
Teplizumab Drug
1 trials
Placebo infusion Drug
1 trials

US sites by state

Facility locations filed on High-risk trials. A trial with sites in several states counts in each.

Washington 1 trials
Texas 1 trials
Tennessee 1 trials
Pennsylvania 1 trials
New York 1 trials
Missouri 1 trials
Minnesota 1 trials
Indiana 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this High-risk page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This High-risk condition card totals 2 registered trials; most-linked intervention Treatment 3: Part 2 of GRIN (Lesson 1, 5-8); top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.